NASDAQ:ALEC Alector Q2 2026 Earnings Report $1.52 0.00 (0.00%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alector EPS ResultsActual EPSN/AConsensus EPS -$0.24Beat/MissN/AOne Year Ago EPSN/AAlector Revenue ResultsActual RevenueN/AExpected Revenue$1.43 millionBeat/MissN/AYoY Revenue GrowthN/AAlector Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Alector Earnings HeadlinesAlector, Inc. (NASDAQ:ALEC) Given Consensus Rating of "Hold" by AnalystsJuly 19, 2026 | americanbankingnews.comGSK ends brain drug alliance with AlectorJuly 9, 2026 | finance.yahoo.comGet “backdoor access” BEFORE the next big IPOWall Street insiders always get first access to pre-IPO shares at the lowest prices, locking in gains before the public ever sees a listing. Dr Mark Skousen says he's found a crack in that system - a backdoor that could let everyday investors get a pre-IPO stake before the announcement hits. Space is limited, and Dr Skousen is revealing the ticker for free right now.July 30 at 1:00 AM | The Oxford Club (Ad)Alector stock plummets 13% as GSK terminates neuroscience pactJuly 9, 2026 | msn.comAlector and GSK partnership to end after dementia, Alzheimer's drug failuresJuly 8, 2026 | reuters.comAlector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy ReadthroughJune 19, 2026 | finance.yahoo.comSee More Alector Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email. Email Address About AlectorAlector (NASDAQ:ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia. The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies. Alector designs its molecules to engage key immune receptors in the brain, seeking to slow or halt disease progression rather than simply address symptoms. Research and development activities are supported by state-of-the-art laboratories in North America and collaborations with academic and industry partners in Europe. Since completing its initial public offering in 2019, Alector has expanded its clinical footprint through strategic alliances and investigator-initiated trials. The company maintains global development programs aimed at bringing the first approved immuno-neurology therapies to patients worldwide. Alector is led by co-founder and Chief Executive Officer Dr. Arnon Rosenthal, a neuroscientist with over two decades of experience in immunology and drug discovery. The management team brings extensive backgrounds in clinical development, regulatory affairs, and commercialization, supporting Alector’s mission to transform the treatment landscape for neurodegenerative diseases.View Alector ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersUnitedHealth Just Gave Wall Street a Clearer Turnaround SignalCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
